Morepen Laboratories Ltd

The Board of Morepen Laboratories at its meeting held on 12 May 2025 has noted the decision of the Board of Directors of Morepen Medipath (formerly known as Morepen Medtech), a subsidiary of the Company, to incorporate a Wholly Owned Subsidiary in the mainland at Dubai, United Arab Emirates. The incorporation of the wholly owned subsidiary is intended to expand both the Business-to-Consumer (B2C) and Business-to-Business (B2B) customer segments and to provide greater access to the medical device business. Upon incorporation, the proposed company will become a step-down subsidiary of Morepen Laboratories. Powered by Capital Market - Live

Net profit of Morepen Laboratories declined 28.15% to Rs 20.32 crore in the quarter ended March 2025 as against Rs 28.28 crore during the previous quarter ended March 2024. Sales rose 10.11% to Rs 465.85 crore in the quarter ended March 2025 as against Rs 423.07 crore during the previous quarter ended March 2024. For the full year,net profit rose 22.73% to Rs 118.02 crore in the year ended March 2025 as against Rs 96.16 crore during the previous year ended March 2024. Sales rose 7.17% to Rs 1811.58 crore in the year ended March 2025 as against Rs 1690.43 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales465.85423.07 10 1811.581690.43 7 OPM %9.0711.44 -9.619.38 - PBDT42.1851.83 -19 184.09168.89 9 PBT25.7142.20 -39 155.11135.42 15 NP20.3228.28 -28 118.0296.16 23 Powered by Capital Market - Live

Morepen Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2025, has recommended a Final Dividend of Rs.0.20 per share (i.e.10%), subject to the approval of the shareholders.Powered by Capital Market - Live

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg and 100 mg tablets as per the protocol submitted. This will be followed by clinical trials as per approved protocols. Resmetirom is a highly promising therapy under development for non-alcoholic steatohepatitis ('NASH'), a serious form of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation, liver damage, and fat accumulation in the liver, potentially leading to scarring (fibrosis), cirrhosis, and even liver cancer. It is often associated with obesity, metabolic syndrome, and type 2 diabetes, and while it can be a silent disease in the early stages, it can progress to severe liver damage if left untreated. As one of the first Indian companies to foray into this therapeutic area, Morepen is strategically positioned to serve both domestic and international markets and is also evaluating out-licencing opportunities with potential marketing partners.Powered by Capital Market - Live

Morepen Laboratories announced the launch of four new products'Ticapen, UdoFix, LycoMore, Acifix in the month of April 2025 to cater the domestic market in addition to Empamore launched last month continuing. This strategic expansion reinforces Morepen's commitment to scaling its finished dosages business while continuing to invest in cutting-edge R&D that powers a robust pipeline of differentiated, high quality medicines. Importantly, all APIs used in these products are manufactured in-house by Morepen at its world-class, USFDA-approved plants, ensuring consistent quality and supply chain control. Powered by Capital Market - Live

The move is aimed at strengthening Morepen's connect with doctors, pharmacies, patients, and healthcare professionals nationwide. It marks a bold step in scaling up the company's formulations business, which currently stands at around Rs 325 crore. Morepen has set its sights on building a Rs 1,000 crore finished dosages segment within the next five years. To achieve this, the company plans aggressive expansion of its medical representative network and deeper market penetration across both urban and rural India. A key driver of this growth will be its pipeline of competitively priced new products already in production. The Indian pharmaceutical market, projected to reach $130 billion by 2030 with an annual growth rate of 8.2%, positions India as the emerging pharmacy of the world'offering a strong runway for players like Morepen. Morepen Laboratories' operations span APIs, medical devices, and finished formulations. The company is a global exporter of six major APIs, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, supporting its expansion into tier-2 and tier-3 cities. The company's consolidated net profit fell 16.6% to Rs 26.69 crore while revenue from operations rose 1.9% to Rs 452.78 crore in Q3 December 2024 over Q3 December 2023. Powered by Capital Market - Live

Morepen Laboratories today announced a bold expansion plan aimed at deepening its connect with doctors, patients, pharmacies, and healthcare professionals across the country. As part of this strategic initiative, the company will add more than 1,000 professionals to its salesforce over the next three years, with over 200 team members expected to join in FY26 alone. This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domes c finished dosage market, said Sushil Suri, Chairman and Managing Director of Morepen Laboratories. With the leadership in our high value APIs, this significant increase in our salesforce and enhanced reach to doctors, pharmacies, and patients, we are se ng the stage for getting a bigger pie in the Indian pharmaceutical market valued at ₹2.38 lakh crore, yielding higher gross margins and be er returns for stakeholders in the long run.'Powered by Capital Market - Live

Loratadine is used to temporarily relieve the symptoms of hay fever (allergy to pollen, dust, or other substances in the air) and other allergies. These symptoms include sneezing, runny nose, and itchy eyes, nose, or throat. Loratadine is also used to treat itching and redness caused by hives. However, loratadine does not prevent hives or other allergic skin reactions. Loratadine is in a class of medications called antihistamines. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. This approval marks a significant milestone for Morepen as it strategically enters one of the world's largest pharmaceutical markets, China. Morepen holds an over 80% market share in the U.S. generics market for Loratadine, making it the undisputed leader in this category. The company has been exporting to the U.S. for over 25 years, with API exports alone valued at approximately Rs 650 crore. This approval further solidifies Morepen's position as the dominant global manufacturer of Loratadine, a widely prescribed second-generation antihistamine and anti-allergy drug used to treat allergic symptoms such as hay fever and chronic urticaria. With this development, Morepen is poised to capture a significant share of the Chinese market while reinforcing its standing in the global pharmaceutical landscape. Kushal Suri, director of sales & marketing at Morepen Laboratories, said, 'The approval by China's NMPA is a testament to Morepen's unwavering commitment to quality, regulatory excellence, and global market expansion.' Further, he added, 'China represents a vast growth opportunity, and this milestone will allow us to meet the increasing demand for high-quality antihistamine and anti-allergy APIs while reinforcing our leadership in global healthcare.' Morepen Laboratories is a leading player in the pharmaceutical and healthcare industry. With a strong presence in APIs, medical devices, and finished formulations, Morepen has consistently demonstrated innovation and market leadership. The company is a global leader in exporting 6 key API products, including Loratadine, Montelukast, Desloratadine, Atorvastatin, and Fexofenadine. In the medical devices segment, Morepen has made remarkable strides in Point of Care (POC) diagnostics, having installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, driving expansion into tier-2 and tier-3 cities. The company's consolidated net profit fell 16.6% to Rs 26.69 crore in Q3 FY25 as against Rs 31.99 crore posted in Q3 FY24. However, revenue from operations rose 1.9% YoY to Rs 452.78 crore in the quarter ended 31 December 2024. Powered by Capital Market - Live

Morepen Laboratories has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for its Loratadine (anti-allergy API). This marks a significant milestone in Morepen's strategic entry into one of the world's largest pharmaceutical markets. Morepen commands an over 80% market share in the US generics market for Loratadine, making it the undisputed leader in its category. The company has been exporting to the US market for over 25 years, its API exports alone are valued at Rs.650 crores. This approval further solidifies Morepen's position as the dominant global manufacturer of Loratadine, a widely prescribed second-generation antihistamine and anti-allergy drug used to treat allergic symptoms such as hay fever and chronic urticaria. With this development, Morepen is poised to capture a significant share of the Chinese market while reinforcing its standing in the global pharmaceutical landscape.Powered by Capital Market - Live